Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06978244 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy Volunteers
A Phase 1 study of Ocular Pain, sponsored by Bausch & Lomb Incorporated.
- Active
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT06978244 is a Phase 1 study of Ocular Pain that is active but no longer recruiting, run by Bausch & Lomb Incorporated. The registered enrollment target is 24 participants. The trial reports 1 study location across 1 state.
The verdict
NCT06978244, a Phase 1 study of Ocular Pain, is active but no longer recruiting, sponsored by Bausch & Lomb Incorporated.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
Single-Center, Phase 1 study to assess the ocular and systemic safety and tolerability of ascending concentrations of topical BL1332 ophthalmic solution eye drops compared with BL1332 vehicle in healthy volunteers, identifying the highest tolerated doses (HTDs)
Conditions Studied
Interventions
- DRUG BL1332 ophthalmic solution
- DRUG BL1332 ophthalmic vehicle
Study Locations (1)
New Jersey
- Site 101 - Fair Lawn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2025-07-29 |
| Est. Completion | 2026-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06978244
The ClinicalTrials.gov registry entry for NCT06978244 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch & Lomb Incorporated, which has 174 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ocular Pain appearing as the primary indexed condition, and to 2 interventions - of which BL1332 ophthalmic solution is the first listed.
NCT06978244 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT06978244 about?
NCT06978244 is a clinical study titled "A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy Volunteers". Single-Center, Phase 1 study to assess the ocular and systemic safety and tolerability of ascending concentrations of topical BL1332 ophthalmic solution eye drops compared with BL1332 vehicle in healthy volunteers, identifying the highest tolerated doses (HTDs)
What is the current status of trial NCT06978244?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2025-07-29. Estimated completion is 2026-11.
What conditions does trial NCT06978244 study?
This clinical trial studies the following conditions: Ocular Pain.
What interventions are being tested in trial NCT06978244?
The interventions under investigation include: BL1332 ophthalmic solution (DRUG), BL1332 ophthalmic vehicle (DRUG).
Who is sponsoring clinical trial NCT06978244?
This trial is sponsored by Bausch & Lomb Incorporated, which has 174 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06978244 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ocular Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.